Related Experiment Video
Updated: Sep 19, 2025
Intestinal Epithelial Regeneration in Response to Ionizing Irradiation
Published on: July 27, 2022
Radiation Therapy for Abdominal or Pelvic Cancer Treatment in Patients with Inflammatory Bowel Disease: A Systematic
Mario El Hayek1, Nabil El Hage Chehade2, Fadi H Mourad3
1Department of Medicine, Mayo Clinic, Jacksonville, FL, USA.
Background:
IBD is considered a relative contraindication to the use of radiation therapy (RT) due to risks of disease exacerbation and GI toxicity. Currently, there are limited available data on how well patients with IBD tolerate RT.
Methods:
An electronic search was conducted on PubMed, Cochrane, Embase, and Medline. Eligible studies consisted of all peer-reviewed articles reporting outcomes of RT use in the treatment of abdominopelvic neoplasms in IBD patients. Evidence on RT outcomes is evaluated, namely GI toxicity and IBD activity.
Results:
A total of 21 articles with 1,226 patients were identified and included. Patients were most commonly treated for prostate cancer (62%). Modes of RT included EBRT (57%), brachytherapy (33%), and stereotactic RT (9%). IBD flares within 6 months of RT ranged between 3.5% and 15%. Risk factors for flares were rectal IBD (p = 0.012) and the concomitant use of chemotherapy and RT (p = 0.02). Common low-grade GI toxicities (grade I-II) were diarrhea (32%) and proctitis (27%). Rectal bleeding ranged from 5 to 23%. Acute grade III-IV GI toxicities ranged between 5 and 23%, while late grade III-IV GI toxicities ranged between 5 and 15%. Patients with IBD receiving RT had significantly higher rates of wound dehiscence and SBO compared to patients without IBD.
Conclusion:
RT in IBD patients can cause acute high-grade toxicity (up to 23%) and late toxicity (up to 15%). Individualized RT decisions considering IBD location and activity are essential. Prospective studies are needed to investigate flares, toxicities, and optimize RT subtypes, doses, and techniques for this population.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
01:21Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD: